Published 1 day ago • loading... • Updated 19 hours agoShow Less IconSalubris Biotherapeutics Announces Updated Phase 1b/2 Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology Congress 2026 Summary by WBOC 16JK06 continued to demonstrate a highly differentiated safety profile for an MMAE ADC among 230 patients in the targetShare menu2 Articles2 ArticlesAllLeftCenter1RightSearch IconSort IconWBOC 16HealthTech HotSpotView articleCaret Right IconReposted by HealthTech HotSpotCenterFactualityOwnershipSalubris Biotherapeutics Announces Updated Phase 1b/2 Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology Congress 2026JK06 continued to demonstrate a highly differentiated safety profile for an MMAE ADC among 230 patients in the target1 day agoRead Full ArticleThink freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribeBlindspot Title And LogoStories disproportionately reported by the Left or the RightSee More BlindspotsCoverage DetailsTotal News Sources2Leaning Left0Leaning Right0Center1Last Updated19 hours agoBias Distribution100% CenterBias Distribution Too Big Arrow IconToo Big Arrow IconCaret Up Icon100% of the sources are Center100% CenterC 100%Untracked biasFactuality Info IconTo view factuality data please Upgrade to PremiumOwnership Info IconTo view ownership data please Upgrade to VantageWBOC 16 broke the news 1 day ago on Friday, October 23, 2026.Too Big Arrow IconCaret Down IconSources are mostly out of (0)Similar News TopicsWilmington, Delaware Plus IconShow AllBlindspot Title And LogoStories disproportionately reported by the Left or the RightSee More BlindspotsSimilar News TopicsWilmington, Delaware Plus IconShow All